Đang chuẩn bị liên kết để tải về tài liệu:
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

A review of therapies for advanced cancers licenced by the EMA between 2009 and 2013 concluded that for more than half of these drugs there was little evidence of overall survival or quality of life benefit. | Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor EGFR and anaplastic lymphoma kinase ALK negative advanced or metastatic non-small cell lung cancer A systematic review and secondary analysis of trials

TÀI LIỆU LIÊN QUAN

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: A population-based cohort study in Ontario, Canada

The association between post-treatment surveillance testing and survival in stage II and III colon cancer patients: An observational comparative effectiveness study

A comparative study of survival models for breast cancer prognostication revisited: The benefits of multi-gene models

Comparative transcriptomic analysis of candidate effectors to explore the infection and survival strategy of Bursaphelenchus xylophilus during different interaction stages with pine trees

Comparative analysis of overall survival in non-small cell lung cancer patients with and without different organ metastases

REPRODUCTIVE, MATERNAL AND CHILD HEALTH IN EASTERN EUROPE AND EURASIA: A COMPARATIVE REPORT

Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: Comparative study

Comparative effectiveness of primary tumor resection in patients with stage III pancreatic adenocarcinoma

Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: A comparative study

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: Realworld analysis of Korean national database